Results 101 to 110 of about 33,645 (209)

ABCA1 deficiency‐induced cholesterol accumulation aggravates colonic epithelial injury in knockout hamsters

Animal Models and Experimental Medicine, EarlyView.
We established ABCA1‐knockout Syrian golden hamsters as a novel and physiologically relevant model for colitis research. When challenged with a high‐fat diet, ABCA1‐deficient hamsters developed exacerbated colonic inflammation and impaired mucosal barrier integrity, driven by intracellular cholesterol accumulation.
Chang Liu, Jingjie Zheng, Sijing Shi, Jianwen Chen, Geroge Liu, Wei Huang, Xunde Xian, Yuhui Wang, Jianglin Fan, Ping Zhu, Xiawen Yang   +10 more
wiley   +1 more source

Machine Learning to Predict Remission Between 6 and 24 Months in Rheumatoid Arthritis: Insights From JAK, an International Registry Collaboration

Arthritis &Rheumatology, EarlyView.
Objective To develop, externally validate, and simplify a machine learning model to predict remission between 6 and 24 months in patients with rheumatoid arthritis (RA) initiating tumor necrosis factor inhibitors, JAK inhibitors, interleukin‐6 inhibitors, abatacept, or rituximab using data from 11 international registries in the JAK‐pot collaboration ...
Zubeyir Salis, Denis Mongin, Denis Choquette, Louis Coupal, Catalin Codreanu, Florenzo Iannone, Roberto Caporali, Tore K. Kvien, Sella Provan, Ruth Fritsch‐Stork, Dan Nordström, Nina Trokovic, Karel Pavelka, Jakub Závada, Ana Rodrigues, Ziga Rotar, Prodromos Sidiropoulos, Irini Flouri, Céline Lamacchia, Michele Iudici, Delphine Courvoisier, Kim Lauper, Axel Finckh   +22 more
wiley   +1 more source

High dose simvastatin and adverse muscle effects

Universa Medicina, 2016
High blood cholesterol, or hyperlipidemia, is a cardiovascular risk factor. Surveys have demonstrated that 35.6% of adults in the United States suffer from hyperlipidemia.(1) Currently there are various therapeutic regimens available for hyperlipidemia ...
Yenny Yenny
doaj   +1 more source

Efficacy and Safety of Nanoencapsulated Sirolimus Plus Pegadricase: Results From the Randomized, Placebo‐Controlled Phase 3 Trials

Arthritis &Rheumatology, EarlyView.
Objective DISSOLVE I and II examined the efficacy and safety of nanoencapsulated sirolimus (NAS) plus pegadricase (NASP) in patients with uncontrolled gout (UG). Methods In these double‐blind, placebo‐controlled Phase 3 trials of NASP, patients were randomized 1:1:1 to infusions of high‐dose (HD) or low‐dose (LD) NAS plus pegadricase (HD NASP, LD NASP,
Herbert S. B. Baraf, Puja P. Khanna, Milan Petronijevic, Mamuka Lortkipanidze, Anand Patel, Kwabena Ayesu, Michael H. Pillinger, Atul Singhal, Joanna Sobierska, Jacquie Christie, Peter Traber, Rehan Azeem, Wesley DeHaan, Hugues Santin‐Janin, Bhavisha Desai, Alan Kivitz   +15 more
wiley   +1 more source

Research Progress on Anti-Hyperlipidemia Peptides Derived from Foods

Hyperlipidemia is a metabolic disorder in which cholesterol (TC) and triglycerides (TGs) in the blood exceed the normal physiological levels. The incidence of the condition has continued to rise in recent years, posing a serious threat to public health ...
Shuxing Chen, Yuyu Zhang, Mingxia Zhao, Li Liang, Kaina Qiao, Lili Zhang, Lishui Chen   +6 more
core   +1 more source

Interaction between Sex and LDLR rs688 Polymorphism on Hyperlipidemia among Taiwan Biobank Adult Participants

, 2020
Hyperlipidemia is one of the strong risk factors for ischemic heart disease. Using the Taiwan Biobank (TWB) database, we evaluated the risk of hyperlipidemia and its interaction with sex and rs688 polymorphism on the low-density lipoprotein receptor ...
Shu-Yi Hsu, Lee Wang, Min-Chen Wu, Oswald Nfor, Chia-Chi Lung, Yin-Tso Liu, Yung-Po Liaw, Disline Tantoh, Horng-Rong Chang   +8 more
core   +1 more source

Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects

British Journal of Clinical Pharmacology, EarlyView.
Aims This work aimed to contextualize glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) and glucose‐dependent insulinotropic polypeptide (GIP) receptor agonists safety and efficacy regarding weight management (WM); we analysed Food and Drug Administration (FDA) Medical Reviews to analyse 14 medications using patient‐exposure year normalization and ...
Aishwarya Prasad, Anshu Arora, Arun Arora, Jeena Vaid, Arif Khan   +4 more
wiley   +1 more source

AASLD practice guidance on drug, herbal, and dietary supplement–induced liver injury

, 2022
Hepatology, EarlyView.
Robert J. Fontana, Iris Liou, Adrian Reuben, Ayako Suzuki, M. Isabel Fiel, William Lee, Victor Navarro   +6 more
wiley   +1 more source

An Analysis of Hyperlipidemia Presence and Its Correlation with Related Diseases

, 2009
[[abstract]]According to the death factor statistics issued by the Department of Health from year 1993 to 2004, heart disease, brain vessel disease, diabetes, and high blood pressure rank high among the common disease. Their collective number of death is
TU TSIE TING
core  

Clozapine:norclozapine ratio as a marker of metabolic risk and therapeutic response and effect of valproate on clozapine levels

British Journal of Clinical Pharmacology, EarlyView.
Aims Clozapine is the most effective antipsychotic in treatment‐resistant schizophrenia. Clozapine causes weight gain and increased diabetes risk. The role of its metabolite norclozapine and clozapine:norclozapine ratio (CLZ/NCLZ) in metabolic effects has been debated.
Susanna Maria Rask, Miina Lamminmäki, Olli Kampman, Mari Hämäläinen, Eeva Moilanen, Niko Seppälä, Anssi Solismaa   +6 more
wiley   +1 more source